Equity Profile

GH

Guardant Health, Inc.

Health CareHealth Care Services$21.4B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on developing blood tests for cancer detection and monitoring....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.30

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$339M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on developing blood tests for cancer detection and monitoring. As part of the healthcare services sector, it plays a crucial role in advancing precision medicine and improving patient outcomes through innovative diagnostic solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

In Q1 2026, Guardant Health reported an EPS of $-0.45, which was better than analyst expectations of $-0.71, marking a significant surprise. However, revenue details were not disclosed, and the stock saw a slight increase of 0.01% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Guardant Health's upcoming earnings, expecting a narrower loss and steady revenue growth. The company has consistently beaten EPS estimates in recent quarters, which may lead to positive sentiment.

Bull Case

If Guardant Health can continue its trend of beating EPS estimates and show solid revenue growth, it could signal strong demand for its cancer detection products, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a sell-off.

Key Metrics to Watch

EPS

$-0.30

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$339M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Guardant Health's EPS come in better than the consensus estimate of $-0.30?

A beat on EPS could reinforce the company's positive momentum and investor confidence, while a miss could raise red flags.

What revenue figures will Guardant Health report, and how do they compare to the consensus of $339M?

Revenue performance is crucial for assessing market demand and the company's growth trajectory, impacting future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Guardant Health's growth potential, especially given its recent track record of beating EPS estimates.

Supporting Evidence

The company has consistently surprised analysts with better-than-expected EPS in the last several quarters.

Options pricing reflects a significant potential move, indicating that the market anticipates volatility that may not align with consensus expectations.

Key Risk

If the EPS comes in at $-0.26 or better, it could challenge the current bearish sentiment and shift market perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to maintain its positive earnings surprise trend and demonstrate revenue growth.

Bull Confirmed If

An EPS of $-0.26 or better, along with revenue exceeding $345M, would confirm the bullish outlook.

Bear Confirmed If

An EPS worse than $-0.36 and revenue below $332M would support the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant Health beats expectations, history suggests the stock could rise around 1.55%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest management's commentary.

Miss

Should the company miss estimates, the stock could see a decline, with historical patterns indicating a potential drop based on past misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Management's outlook on market demand for cancer detection tests.
3Details on cost management and operational efficiency improvements.
4Insights into competitive positioning within the healthcare diagnostics space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on developing blood tests for cancer detection and monitoring....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-0.30

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$339M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Guardant Health can continue its trend of beating EPS estimates and show solid revenue growth, it could signal strong demand for its cancer detection products, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its growth prospects and lead to a sell-off.

Key Metrics to Watch

EPS

$-0.30

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$339M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Guardant Health's EPS come in better than the consensus estimate of $-0.30?

A beat on EPS could reinforce the company's positive momentum and investor confidence, while a miss could raise red flags.

What revenue figures will Guardant Health report, and how do they compare to the consensus of $339M?

Revenue performance is crucial for assessing market demand and the company's growth trajectory, impacting future projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Guardant Health's growth potential, especially given its recent track record of beating EPS estimates.

Supporting Evidence

The company has consistently surprised analysts with better-than-expected EPS in the last several quarters.

Options pricing reflects a significant potential move, indicating that the market anticipates volatility that may not align with consensus expectations.

Key Risk

If the EPS comes in at $-0.26 or better, it could challenge the current bearish sentiment and shift market perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to maintain its positive earnings surprise trend and demonstrate revenue growth.

Bull Confirmed If

An EPS of $-0.26 or better, along with revenue exceeding $345M, would confirm the bullish outlook.

Bear Confirmed If

An EPS worse than $-0.36 and revenue below $332M would support the bearish case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant Health beats expectations, history suggests the stock could rise around 1.55%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest management's commentary.

Miss

Should the company miss estimates, the stock could see a decline, with historical patterns indicating a potential drop based on past misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or clinical trial results.
2Management's outlook on market demand for cancer detection tests.
3Details on cost management and operational efficiency improvements.
4Insights into competitive positioning within the healthcare diagnostics space.